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What is the Best Way to Define the Antimelanocyte T Cell
Repertoire?
To the Editor:
Melanomas are most frequently infiltrated by activated lympho-
cytes. With the exception of rare spontaneous, immune-mediated
regressions of melanomas or in the halo nevus phenomenon,
the ongoing melanocyte-specific T cell responses are inefficient,
and malignant melanocytic tumors escape the immune control.
Thus, the understanding of the mechanisms underlying the
switch towards efficient/inefficient T cell responses is of primary
importance for the immunotherapy of melanomas. In recent
years, research has focused on the identification of the T cell
clones that infiltrate melanomas and are able to drive an efficient
response. These investigations have been carried out by using
either T cell clones expanded in vitro, or reverse transcriptase-
polymerase chain reaction (PCR) analysis of mRNA encoding
the T cell receptor (TCR)-β and -α chains isolated from
biopsies. The paper by Strohal et al (1998) in the Journal
describes such an attempt of approaching the TCR repertoire
in primary and metastatic melanomas. The authors semiquantitated
the TCR-BV and -AV usages in 12 autopsy specimens biopsied
in various organs of three melanoma patients. Only subsets of
TCR-BV and -AV families were found expanded in the different
biopsies. A limited number of CDR3 sequences was detected
in locally expanded TCR-BV/AV families, although no CDR3
sequence was shared by all metastatic sites of a patient. The
authors claimed that site-specific oligoclonal expansions occurred
in the patients, a finding possibly indicative either of the
recognition of different antigens due to tumor progression, or
of the local selection of different T cell clones nevertheless
recognizing the same molecular target.
The authors do not quote some important papers in the field,
however, nor do they discuss the issue that their PCR-based
technology may not have been sensitive enough to detect
nominal, antigen-driven T cell responses: in an earlier study on
the T cell repertoire in melanomas, it was shown that the
expansion of a T cell population bearing a particular TCR-β
chain may not result in an increase of a BV usage detectable
either by blot hybridization or by FACS analysis (Puisieux et al,
1994). Thus the latter techniques do not generate an accurate
picture of antigen-driven T cell responses. These limitations
explain why alternative techniques have been designed to describe
the T cell repertoire in tumor-infiltrating lymphocytes (TIL)
and in various other pathologic conditions (Pannetier et al,
1998). In the ‘‘immunoscope’’ technique developed in our
laboratory, the BV-BC amplification products are subjected to
primer extension reactions primed using either an internal BC-
specific primer, or each of the 13 fluorescently labelled BJ-
specific primers. The ‘‘run-off’’ DNA encompasses the CDR3
region of the β chain of the TCR, a region that recognizes
the antigenic peptides bound to MHC molecules. Run-off
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products are analyzed in an automated DNA sequencer in order
to determine the length spectrum of the CDR3 regions as well
as the intensity of fluorescence of each peak. The distribution
of the intensity of fluorescence as a function of the CDR3
length yields a Gaussian pattern in complex T cell populations
like BL, whereas antigen-driven responses yield pre-eminent
peaks, which distorts the Gaussian distribution. This procedure
generates a kind of snapshot of the T cells present in TIL. The
immunoscope technique, which generates up to 2000 independent
signals out of as few as 10,000 T cells, is semiquantitative.
Moreover, the cDNA peaks of interest can be isolated and
sequenced. This approach defining the T cell expansions of
interest has been used in a variety of pathologic conditions
(Musette et al, 1996; Bachelez et al, 1998; David-Ameline et al,
1996; Faure et al, 1998).
Several studies on T cells infiltrating melanocytic tumors have
been conducted using the immunoscope approach. The complex
behavior of the T cells infiltrating melanomas has been studied
by Puisieux et al (1994) and T cell clones undergoing expansion
were characterized, some of which were found infiltrating all
tumor sites of the patients, a finding conflicting with the
conclusion reached by Strohal et al. Furthermore, we have
recently analyzed the diversity of the TCR-β chains used by
T cells infiltrating nevi undergoing immune-mediated regression
(Musette et al, 1999). Two distinct populations of T cells
infiltrating the halo nevi can be distinguished: nonactivated or
polyclonally activated T cells, and highly restricted, clonally
expanded T cells. In addition, the T cells clonally expanded at
one site were repeatedly found in several halo nevi concomitently
analyzed in the same patient. Under the assumption that the
cells share the same rearranged TCR-α chain, the expanded
cells derive from the same α/β T cell clones and should thus
recognize the same molecular target(s), although the latter is
(are) located at different sites in the skin. Using a different
strategy, efficient antitumor responses in spontaneously regressing
melanomas have also been found to be oligoclonal (Ferradini
et al, 1993). Thus, it is tempting to suggest that expansion of
the same clones at distinct sites is a clue to the in vivo efficiency
of T cells in malignant diseases, whereas inefficient T cell
responses would be polyclonal or site-specific.
The ability to obtain a rapid characterization of the T cell
clones of a patient that are candidates for supporting a specific
antimelanocyte response is a key issue for the understanding of
the mechanisms that usually make specific T cells unable to
control cell progression. The faster candidate clones are defined
by PCR-based technologies, the faster their functional properties
can be ascertained and their specificity determined, whereas their
sorting out can be achieved using the proper MHC tetramers
loaded with specific peptides. We believe that coupling these
two approaches should allow the optimal monitoring of the
evolution of T cell expansions in melanomas and in solid tumors
in general.
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Reply
We thank Drs. Musette et al for their interesting comments on
our study ‘‘First comparative delineation of the T-cell receptor
repertoire in primary and multiple subsequent/coexisting
metastatic melanoma sites’’ (Strohal et al, 1998) and offer the
following reply.
The value of phenotypic TCR analyses for a reliable
monitoring of tumor-triggered host responses in situ is directly
dependant on their capacity to follow TCR moieties expressed
by potentially tumor-reactive lymphocytes. Based on the
observation that antigen-driven T cell responses are able to
induce the generation of numerically expanded and clonally
restricted TCR specificities (Hedrick and Eidelman, 1993; Weiss,
1993), there exist two different strategies for the identification
of those BV specificities that are likely to comprise functionally
relevant TCR clonotypes. The vast majority of investigators,
including ourselves, are using a semiquantitative PCR and
Southern blot technique to identify certain BV specificities on
the basis of their numerical predominance (TCRBV melanoma/
mean 1 2SD TCR-BV PBL ù 1) within the TCR repertoire
of a given melanoma specimen (reviewed in Sensi and Parmiani,
1995), and are then analysing the clonal status of all the
dominating BV-associated TCR transcripts by producing and
screening BV-BC fragment libraries with a final CDR3 region-
sequencing procedure of library-related TCR cDNA clones. In
contrast, Musette et al consider the parameter of CDR3 region
clonality as a major decision criterion for the selection of BV
families to be further analyzed, and have developed a detection
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system, the immunoscope technique, which initially defines the
overall CDR3 region length polymorphism of each BV specificity
expressed by TIL of the respective melanoma specimen (Pannetier
et al, 1998). Musette et al favor this experimental approach on
the basis of phenotypic TCR data (Puisieux et al, 1994), showing
that the expansion of a clonal T cell population does not always
result in an overall increased expression of the related BV gene
segment. Consequently, they are suggesting that semiquantitative
procedures do not generate an accurate picture of antigen-driven
immune responses. Due to ample evidence from their own
previous data and different functional studies from the literature
indicating that both techniques are leading to, at least, equally
reliable results, we cannot accept the authors’ objection. In
detail, a phenotypic and functional study by Bachelez et al
(1998) using both the semiquantitative PCR/Southern blot
technology and the immunoscope technique clearly demonstrated
that those BV families presenting with oligoclonal or clonal
peaks (patient A/SIL1: BV8 and BV16, patient C/SIL1: BV8)
were also numerically predominating the TCRBV repertoire in
the respective skin lesions, and, with regard to BV8-expressing,
CD81 lesion-derived cell lines, also harbored functional TCR
clonotypes. In addition, even in the work by Puisieux et al
(1994) that has been cited by the authors to support their
statement, the only BV specificity that comprises TCR clonotypes
shared by all melanoma specimens and PBL (patient BON/BV3)
is the one which, on a semiquantative basis, is part of the small
group of BV families dominating the TCR repertoire in the
specimens tested. Moreover, various mouse and human studies
targeting the important question, whether the clonal expansion
of certain tumor-reactive TCR transcripts is leading to a
numerical expression peak of the overall related BV family,
showed that, indeed, those TCR clonotypes that carried the in
situ predominating BV specificities also displayed specific HLA
class 1-restricted lytic activity against autologous melanoma cells
in vitro (Ferradini et al, 1993; Mackensen et al, 1994; Kurt et al,
1995; Sensi et al, 1997). Thus, it is very likely that functionally
relevant T cell mediated responses in situ are characterized by
clonal restriction as well as numerical expansion. Following this
rationale, we actually did not intend to establish and perform a
highly stringent PCR technology that might lead to the
identification of numerous different clonal TCR transcripts just
representing minute portions of tumor-related TIL. Nevertheless,
our screening procedure of BV-BC cDNA libraries did provide
enough sensitivity to demonstrate that certain TCR clonotypes
shared by multiple tumor deposits often presented with site-
specific quantitative differences of expression, in that they
undergo a major expansion in one of the respective sites only.
In fact, these findings are compatible with the conclusion of
Musette et al that expansion of the same clones at distinct sites
is a clue to the in vivo efficiency of T cells in malignant diseases.
We also have difficulties in accepting the authors’ concern
regarding major discrepancies between our data and studies by
Puisieux et al (1994) and Musette et al (1999) characterizing the
diversity of TCR-β-chains in multiple melanoma specimens and
halo nevi, respectively. Identifying T cell clones that are
infiltrating all halo nevi and melanoma deposits of a given
patient, these authors conclude that the results of our study lacking
such identical CDR3 region sequences at all tumor sites might not
create an authentic picture of T cell mediated host responses in
the patients investigated. The authors, however, are referring to
studies that were analysing different material as compared with our
work. While Drs. Puisieux and Musette delineated skin-associated
TCR configurations in subcutaneous metastases (together with one
affected lymph node and PBL used for control purposes) as well as
nevi, we were dealing with multiple metastatic specimens from
different nonskin-related organ sites. In this context we would like
to emphasize previous reports from our laboratory showing that (i)
TIL within cutaneous lesions often express the cutaneous leukocyte
antigen (CLA), whereas lymphocytes infiltrating extracutaneous
tumor deposits do not display this skin-homing receptor (Strohal
